- Ticker
- ABEO
- Price
- 2.40
- Stock movement down
- -0.05 (-2.04%)
- Company name
- Abeona Therapeutics Inc
- Exchange
- (NASDAQ ,
- Currency
- USD )
- Sector
- Healthcare >Biotechnology
- Capitalización del mercado
- 41.22M
- Valor de Ent
- 58.84M
- Precio/Ventas
- 9.48
- Precio/Reservar
- 2.67
- Rendimiento del div.
- -
- Crecimiento del div.
- -
- Años de crecimiento
- -
- Pago FCF
- -
- Seguimiento de P/E
- -
- P/E A plazo
- -
- PEG
- -
- EPS crecimiento
- -
- Rendimiento a 1 año
- 727.59%
- Rendimiento a 3 años
- 4.06%
- Rendimiento a 5 años
- -30.24%
- Rendimiento a 10 años
- -20.25%
Última actualización: 2023-03-22
Get the latest news and real-time alerts from Abeona Therapeutics Inc. (ABEO) stock at Seeking Alpha.
29 de marzo de 2023
iO Charts is a Seeking Alpha partner
Get the latest news and real-time alerts from Abeona Therapeutics Inc. (ABEO) stock at Seeking Alpha.
1 de diciembre de 2022
iO Charts is a Seeking Alpha partner
DIVIDENDOS
ABEO no paga dividendos
Get the latest news and real-time alerts from Abeona Therapeutics Inc. (ABEO) stock at Seeking Alpha.
14 de noviembre de 2022
iO Charts is a Seeking Alpha partner
Get the latest news and real-time alerts from Abeona Therapeutics Inc. (ABEO) stock at Seeking Alpha.
3 de noviembre de 2022
iO Charts is a Seeking Alpha partner
VALORACIÓN
Relaciones de valoración
Loading...
Datos de relaciones de valoración
| Seguimiento de P/E | - |
| Precio de OCF | - |
| Precio de FCF | - |
| Precio de EBITDA | - |
| EV a EBITDA | - |
Valoración (ventas/valor contable)
Loading...
Datos de valoración (ventas/valor contable)
| Precio de venta | 9.48 |
| Precio para reservar | 2.67 |
| EV a ventas | 13.54 |
Get the latest news and real-time alerts from Abeona Therapeutics Inc. (ABEO) stock at Seeking Alpha.
3 de noviembre de 2022
iO Charts is a Seeking Alpha partner
Results from the pivotal VITAL study, using EB-101 for the treatment of patients with RDEB are expected to be released before the end of 2022. Read more here.
19 de octubre de 2022
iO Charts is a Seeking Alpha partner
FINANZAS
Por acción
Loading...
Datos por acción
| Recuento actual de acciones | 17.18M |
| EPS (TTM) | -13.28 |
| FCF por acción (TTM) | -7.64 |
Declaración de ingresos
Loading...
Datos de la declaración de ingresos
| Ingresos (TTM) | 4.35M |
| Beneficio bruto (TTM) | 4.00M |
| Ingresos operativos(TTM) | -84.63M |
| Ingresos netos (TTM) | -85.25M |
| EPS (TTM) | -13.28 |
| EPS (a 1 año) | -1.79 |
Márgenes
Loading...
Datos de márgenes
| Margen bruto (TTM) | 91.95% |
| Margen operativo (TTM) | -1947.33% |
| Margen de beneficios (TTM) | -1961.64% |
Balance
Loading...
Por favor, cree una cuenta gratuita o inicie sesión para acceder a este gráfico
Datos de balance
| Efectivo | 5.73M |
| Créditos netos | 1.05M |
| Total de activos corrientes | 25.50M |
| Fondo de comercio | 0.00 |
| Activos intangibles | 0.00 |
| Propiedad, planta y equipo | 0.00 |
| Activos totales | 38.76M |
| Cuentas por pagar | 1.75M |
| Deuda actual a corto/largo plazo | 8.29M |
| Total de pasivos corrientes | 12.60M |
| Total de pasivos | 23.35M |
| Fondos propios de los accionistas | 15.41M |
| Activos tangibles netos | 15.41M |
Flujo de efectivo
Loading...
Por favor, cree una cuenta gratuita o inicie sesión para acceder a este gráfico
Datos de flujo de efectivo
| Flujo de caja operativo (TTM) | -46.16M |
| Gastos de capital (TTM) | 2.91M |
| Flujo libre de efectivo (TTM) | -49.07M |
| Dividendos pagados (TTM) | 0.00 |
Rendimiento financiero
Loading...
Por favor, cree una cuenta gratuita o inicie sesión para acceder a este gráfico
Datos de rendimiento financiero
| Rendimiento de los fondos propios | -553.12% |
| Rendimiento de los activos | -219.95% |
| Rendimiento del capital invertido | -495.00% |
| Rendimiento de efectivo del capital invertido | -284.93% |
Get the latest news and real-time alerts from Abeona Therapeutics Inc. (ABEO) stock at Seeking Alpha.
4 de octubre de 2022
iO Charts is a Seeking Alpha partner
Get the latest news and real-time alerts from Abeona Therapeutics Inc. (ABEO) stock at Seeking Alpha.
3 de octubre de 2022
iO Charts is a Seeking Alpha partner
INFORMACIÓN SOBRE LAS ACCIONES
Gráfico de acciones
Loading...
Datos sobre el precio de las acciones
| Abierto | 2.46 |
| Máximo diario | 2.49 |
| Mínimo diario | 2.38 |
| Volumen diario | 49K |
| Máximo histórico | 47188.00 |
| Estimación de analistas a 1 año | 21.33 |
| Beta | 1.25 |
| EPS (TTM) | -13.28 |
| Dividendo por acción | - |
| Fecha ex-div | 22 Jul 2022 |
| Próxima fecha de beneficios | 29 Mar 2023 |
Potencial de desventaja
Loading...
Datos del potencial de desventaja
| ABEO | S&P500 | |
| Caída del precio actual desde el máximo histórico | -99.99% | -17.92% |
| La mayor caída de precio | -100.00% | -56.47% |
| Fecha de la mayor caída | 17 Jun 2022 | 9 Mar 2009 |
| Caída promedio del máximo | -92.06% | -11.51% |
| Tiempo promedio para un nuevo máximo | 406 days | 13 days |
| Tiempo máximo hasta el nuevo máximo | 7600 days | 1805 days |
The following slide deck was published by Abeona Therapeutics Inc.
17 de agosto de 2022
iO Charts is a Seeking Alpha partner
Get the latest news and real-time alerts from Abeona Therapeutics Inc. (ABEO) stock at Seeking Alpha.
11 de agosto de 2022
iO Charts is a Seeking Alpha partner
DETALLES DE LA EMPRESA
Mercado
41.22M
Categoría de Mercado
Small-cap
Descripción
Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, develops gene and cell therapies for life-threatening rare genetic diseases. Its lead program is EB-101, an autologous, gene-corrected cell therapy that is in Phase III clinical trial for recessive dystrophic epidermolysis bullosa. The company also develops ABO-102, an adeno-associated virus (AAV)-based gene therapy for Sanfilippo syndrome type A; ABO-201 to treat CLN3 disease; ABO-401 for the treatment of cystic fibrosis; and ABO-50X for the treatment of genetic eye disorders. In addition, it is developing AAV-based gene therapy through its AIM vector platform programs. The company was formerly known as PlasmaTech Biopharmaceuticals, Inc. and changed its name to Abeona Therapeutics Inc. in June 2015. Abeona Therapeutics Inc. was incorporated in 1974 and is headquartered in New York, New York.
Empleados
90
Sitio web
Relaciones con inversionistas
-
Archivos de la SEC
CEO
Joao Siffert
País
USA
Ciudad
New York
Tipo de acciones
Common stock
CCC estatus
-
Frecuencia de Dividendos
-
EVENTOS Y PRESENTACIONES
EventosPresentaciones
Loading...
Get the latest news and real-time alerts from Abeona Therapeutics Inc. (ABEO) stock at Seeking Alpha.
20 de julio de 2022
iO Charts is a Seeking Alpha partner
Get the latest news and real-time alerts from Abeona Therapeutics Inc. (ABEO) stock at Seeking Alpha.
5 de julio de 2022
iO Charts is a Seeking Alpha partner
ENTENDER EL NEGOCIO
Loading...
Get the latest news and real-time alerts from Abeona Therapeutics Inc. (ABEO) stock at Seeking Alpha.
19 de mayo de 2022
iO Charts is a Seeking Alpha partner
Abeona Therapeutics Inc.'s (ABEO) CEO Vishwas Seshadri on Q1 2022 Results - Earnings Call Transcript
Abeona Therapeutics Inc. (NASDAQ:NASDAQ:ABEO) Q1 2022 Earnings Conference Call May 17, 2022 8:30 AM ETCompany ParticipantsVishwas Seshadri - Chief Executive OfficerJoseph Vazzano - Chief...
17 de mayo de 2022
iO Charts is a Seeking Alpha partner
NOVEDADES DE LA EMPRESA
Todas las novedadesComunicados de prensa
We can readily understand why investors are attracted to unprofitable companies. For example, although...
31 de marzo de 2023
Expects to submit BLA for EB-101 to FDA in late-2Q/early-3Q 2023 based on positive Phase 3 VIITAL™ study results announced in 4Q 2022 Advancing AAV-based gene therapy candidates toward IND studies in ...
29 de marzo de 2023
NEW YORK and CLEVELAND, March 24, 2023 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced it has granted equity awards to new employees who joined Abeona. On March 23, 2023, A...
24 de marzo de 2023
NEW YORK and CLEVELAND, March 16, 2023 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced that additional data from its pivotal Phase 3 VIITAL™ study of EB-101 for recessive d...
16 de marzo de 2023
Advancing AAV-based gene therapy candidates toward IND studies on encouraging animal proof of concept data in Stargardt Disease, X-linked Retinoschisis (XLRS), and Autosomal Dominant Optic Atrophy (AD...
14 de marzo de 2023
Following positive topline data from Phase 3 VIITAL™ study of EB-101 with both co-primary endpoints met, Abeona plans to submit BLA to U.S. FDA in 2Q 2023 Company well-funded with expected cash runway...
14 de noviembre de 2022
Cantor Fitzgerald raised the price target on Abeona Therapeutics Inc (NASDAQ: ABEO) from $22 to $40 after adjusting the market model/ increasing the probability of success for EB-101. Last week, the c...
8 de noviembre de 2022
Abeona Therapeutics Inc (NASDAQ: ABEO) announced topline data from its pivotal Phase 3 VIITAL study of EB-101 for recessive dystrophic epidermolysis bullosa (RDEB). The VIITAL study met its two co-pri...
3 de noviembre de 2022
NEW YORK and CLEVELAND, Nov. 03, 2022 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) announced today that it has entered into a securities purchase agreement to sell 7,065,946 shares of i...
3 de noviembre de 2022
Co-primary endpoint measuring >50% wound healing, other endpoints measuring >75% and complete wound healing at six months all met Co-primary endpoint measuring pain reduction at six months met; greate...
3 de noviembre de 2022
Página siguiente
Get the latest news and real-time alerts from Abeona Therapeutics Inc. (ABEO) stock at Seeking Alpha.
17 de mayo de 2022
iO Charts is a Seeking Alpha partner
Get the latest news and real-time alerts from Abeona Therapeutics Inc. (ABEO) stock at Seeking Alpha.
13 de mayo de 2022
iO Charts is a Seeking Alpha partner